2-Pyridineacetamide, N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[(3R)-3-[(1-oxo-2-butyn-1-yl)amino]-1-piperidinyl]-
![2-Pyridineacetamide, N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[(3R)-3-[(1-oxo-2-butyn-1-yl)amino]-1-piperidinyl]- Structure](CAS/20240320/GIF/2448172-10-7.gif)
- CAS No.
- 2448172-10-7
- Chemical Name:
- 2-Pyridineacetamide, N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[(3R)-3-[(1-oxo-2-butyn-1-yl)amino]-1-piperidinyl]-
- Synonyms
- 2-Pyridineacetamide, N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[(3R)-3-[(1-oxo-2-butyn-1-yl)amino]-1-piperidinyl]-
- CBNumber:
- CB813944841
- Molecular Formula:
- C32H34N8O3
- Molecular Weight:
- 578.67
- MDL Number:
- MOL File:
- 2448172-10-7.mol
2-Pyridineacetamide, N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[(3R)-3-[(1-oxo-2-butyn-1-yl)amino]-1-piperidinyl]- Chemical Properties,Uses,Production
Description
BMF-219 is the first and only covalent menin inhibitor in clinical development and is being evaluated in multiple hematologic malignancies, solid tumours, and diabetes mellitus. COVALENT-101 (NCT05153330) is a Phase I dose-escalation and -expansion study of BMF-219 in R/R AL, DLBCL, MM, and CLL.
Uses
BMF-219 is a covalently binding inhibitor of menin, a protein that plays an essential role in oncogenic signaling in genetically defined leukemias and diabetes. Preclinically, BMF-219 has demonstrated in well-established acute leukemia cell lines robust downregulation of essential leukemogenic genes in addition to menin itself. Additionally, BMF-219 has shown anticancer activity in multiple in vitro, in vivo, and ex vivo models of acute leukemia, multiple myeloma, diffuse large B-cell lymphoma and chronic lymphocytic leukemia. BMF-219 is currently being evaluated in first-in-human clinical trials enrolling patients with specific menin-dependent mutations in liquid and solid tumours and patients with diabetes.